Hoffman Tomer, Haviv Yael, Cohen Amir, Nesher Lior, Schlaeffer-Yosef Tal, Azulay Hovav, Brosh-Nissimov Tal, Amit Sharon, Gazit Zeala, Tribble David R, Ben-Ami Ronen, Yahav Dafna
Infectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Faculty of Medicine & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
Mycoses. 2025 Feb;68(2):e70028. doi: 10.1111/myc.70028.
Available data on combat wound-related invasive mould infections (IMIs) are limited.
We aimed to describe the characteristics and outcomes of IMIs in casualties of a recent conflict.
PATIENTS/METHODS: A retrospective study including hospitalised patients with combat-related injuries, fulfilling criteria for wound-related IMI based on Trauma Infectious Disease Outcomes Study definitions. Patient and injury characteristics, management and outcomes are described and compared to previous cohorts. Mould isolates and susceptibility testing results, including the novel agent manogepix, are reported.
Overall, 31 patients (69 mould isolates) were included-resulting in an IMI incidence rate of 1.9%. Blast was the most common injury mechanism (71%), with limb amputations and abdominoperineal injuries in 35% and 45%, respectively. Mould cultures, obtained mostly from lower extremities wounds (62%), were positive in all patients. Most (68%) had poly-mould infections, with Aspergillus and Fusarium species predominating. Overall, non-susceptibility rates of > 50% to newer azoles and 38% to amphotericin B reflected the high proportion of Fusarium spp., A. terreus and A. flavus, with the lowest azole minimal inhibitory concentrations demonstrated with posaconazole. Manogepix displayed good in-vitro activity against all isolates, except for Mucorales species. Two patients (6.5%) died of disseminated IMIs and 19% required amputations. Patients with Mucorales had poorer outcomes (40% mortality/amputation vs. 19% for non-Mucorales).
Combat wound-related IMIs are uncommon but carry significant morbidity and mortality. High susceptibility rates to manogepix were observed. Further studies are needed to evaluate optimal surgical approaches and the role of antifungal susceptibility testing in this setting.
关于战斗创伤相关侵袭性霉菌感染(IMIs)的现有数据有限。
我们旨在描述近期冲突中伤员IMIs的特征和结局。
患者/方法:一项回顾性研究,纳入因战斗相关损伤住院且根据创伤传染病结局研究定义符合伤口相关IMIs标准的患者。描述患者和损伤特征、治疗及结局,并与既往队列进行比较。报告霉菌分离株及药敏试验结果,包括新型药物曼奇匹克。
总体纳入31例患者(69株霉菌分离株),IMIs发病率为1.9%。爆炸伤是最常见的损伤机制(71%),截肢和腹部会阴伤分别占35%和45%。霉菌培养大多取自下肢伤口(62%),所有患者培养结果均为阳性。多数(68%)为多霉菌感染,以曲霉菌和镰刀菌属为主。总体而言,对新型唑类药物不敏感率>50%,对两性霉素B不敏感率为38%,这反映了镰刀菌属、土曲霉和黄曲霉比例较高,泊沙康唑的唑类最低抑菌浓度最低。曼奇匹克对除毛霉目以外的所有分离株均显示出良好的体外活性。2例患者(6.5%)死于播散性IMIs,19%的患者需要截肢。毛霉目的患者结局较差(死亡率/截肢率为40%,非毛霉目为19%)。
战斗创伤相关IMIs虽不常见,但具有显著的发病率和死亡率。观察到对曼奇匹克的高敏感性。需要进一步研究以评估最佳手术方法及抗真菌药敏试验在此情况下的作用。